Epidermal Growth Factor Receptors with Tyrosine Kinase Domain Mutations Exhibit Reduced Cbl Association, Poor Ubiquitylation, and Down-regulation but Are Efficiently Internalized
- 15 August 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 67 (16) , 7695-7702
- https://doi.org/10.1158/0008-5472.can-07-0484
Abstract
Some non–small cell lung cancers (NSCLC) with epidermal growth factor receptor (EGFR) tyrosine kinase domain mutations require altered signaling through the EGFR for cell survival and are exquisitely sensitive to tyrosine kinase inhibitors. EGFR down-regulation was impaired in two NSCLCs with EGFR tyrosine kinase domain mutations. The mutant receptors were poorly ubiquitylated and exhibited decreased association with the ubiquitin ligase Cbl. Overexpression of Cbl increased the degradation of EGFR. Treatment with geldanamycin, an inhibitor of the chaperone heat shock protein 90, also increased both wild-type and mutant EGFR degradation without affecting internalization. The down-regulation of the mutant EGFRs was still impaired when they were stably expressed in normal human bronchial epithelial cells. Thus, the mutations that altered signaling also decreased the interaction of EGFRs with the mechanisms responsible for endosomal sorting. [Cancer Res 2007;67(16):7695–702]Keywords
All Related Versions
This publication has 34 references indexed in Scilit:
- Epidermal growth factor receptor mutations in lung cancerNature Reviews Cancer, 2007
- Association with HSP90 Inhibits Cbl-Mediated Down-regulation of Mutant Epidermal Growth Factor ReceptorsCancer Research, 2006
- Multiple Oncogenic Changes (K-RASV12, p53 Knockdown,Mutant EGFRs, p16Bypass, Telomerase) Are Not Sufficient to Confer a Full Malignant Phenotype on Human Bronchial Epithelial CellsCancer Research, 2006
- Regulation of Epidermal Growth Factor Receptor Down-Regulation by UBPY-mediated Deubiquitination at EndosomesMolecular Biology of the Cell, 2005
- Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutantsOncogene, 2005
- AMSH is an endosome-associated ubiquitin isopeptidaseThe Journal of cell biology, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Escape from Cbl-mediated downregulationCancer Cell, 2003
- A mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signalingThe EMBO Journal, 2002